ResearcherActive in the last 2 years
Howard W. Bruckner
Matched on ORCID iD 0000-0002-7459-7255; OpenAlex author ID A5019770125. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 4
- Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer. Co-author DOI 10.1002/cncr.70509↗
- Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with De… Co-author DOI 10.3892/mco.2021.2348↗
- A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. First author DOI 10.1016/j.omto.2018.12.005↗
- Stereotactic radiosurgery plays a critical role in enhancing long-term survival in a patient with pancreatic cancer metastatic to the brain. Co-author PMID 24023326↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elisheva Knopf · 1 shared paper, 2026 · strength 0.63
- Sant P. Chawla · 2 shared papers, 2019–2021 · strength 0.27
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
- Erlinda Maria Gordon · 2 shared papers, 2019–2021 · strength 0.27
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
- Michael Andrew Morse · 2 shared papers, 2019–2021 · strength 0.27
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
- Susan C. Pannullo · 1 shared paper, 2013 · strength 0.03
- Prajwal Rajappa · 1 shared paper, 2013 · strength 0.03
- Robert Lance Fine · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.